Payment overview · 2025
General Payments
$1,273.70
27 reported records · 9 companies
Healthcare provider profile · identity verified
Chistopher Nguyen Do, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN JOSE, CA · NPI 1407876659
Verified facts
What the public records show
CMS Open Payments records show Chistopher Nguyen Do, M.D. received $1,273.70 in general payments during 2025 across 27 reported records.
Amgen Inc. accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Rybelsus, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $517.69 | 40.6% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $264.29 | 20.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $185.86 | 14.6% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $150.00 | 11.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.76 | 3.5% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.62 | 2.7% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $33.77 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.35 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.36 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,273.70 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $265.31 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $217.55 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $210.65 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $206.22 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $188.57 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $155.12 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $112.59 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $112.59 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $34.62 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $33.77 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $33.77 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC | $33.77 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 278 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 205 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
278 | 81 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
205 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
205 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1456 | 463 |
| Amlodipine Besylate | Amlodipine Besylate | 1016 | 328 |
| Losartan Potassium | Losartan Potassium | 883 | 282 |
| Omeprazole | Omeprazole | 536 | 204 |
| Gabapentin | Gabapentin | 500 | 213 |
| Metformin Hcl | Metformin Hcl | 425 | 140 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 423 | 148 |
| Pioglitazone Hcl | Pioglitazone Hcl | 389 | 130 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 361 | 143 |
| Montelukast Sodium | Montelukast Sodium | 352 | 133 |
| Tamsulosin Hcl | Tamsulosin Hcl | 344 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 338 | 118 |
| Lisinopril | Lisinopril | 288 | 86 |
| Fluticasone Propionate | Fluticasone Propionate | 286 | 109 |
| Diclofenac Sodium | Diclofenac Sodium | 280 | 126 |
| Farxiga | Dapagliflozin Propanediol | 278 | 81 |
| Alendronate Sodium | Alendronate Sodium | 274 | 84 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 257 | 82 |
| Simvastatin | Simvastatin | 250 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 61 |
| Celecoxib | Celecoxib | 244 | 112 |
| Azelastine Hcl | Azelastine Hcl | 239 | 64 |
| Memantine Hcl | Memantine Hcl | 236 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 231 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 75 |
| Famotidine | Famotidine | 221 | 83 |
| Metformin Hcl Er | Metformin Hcl | 220 | 72 |
| Jardiance | Empagliflozin | 205 | 57 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 203 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 78 |
| Sildenafil Citrate | Sildenafil Citrate | 188 | 40 |
| Donepezil Hcl | Donepezil Hcl | 184 | 62 |
| Januvia | Sitagliptin Phosphate | 178 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 167 | 73 |
| Glipizide | Glipizide | 162 | 52 |
| Tramadol Hcl | Tramadol Hcl | 153 | 49 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 149 | 122 |
| Atenolol | Atenolol | 149 | 42 |
| Hydrocortisone | Hydrocortisone | 144 | 50 |
| Levofloxacin | Levofloxacin | 137 | 115 |
| Clonidine Hcl | Clonidine Hcl | 136 | 47 |
| Meclizine Hcl | Meclizine Hcl | 129 | 64 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 128 | 33 |
| Allopurinol | Allopurinol | 122 | 44 |
| Vascepa | Icosapent Ethyl | 122 | 27 |
| Carvedilol | Carvedilol | 121 | 47 |
| Raloxifene Hcl | Raloxifene Hcl | 112 | 37 |
| Verapamil Er | Verapamil Hcl | 109 | 35 |
| Doxazosin Mesylate | Doxazosin Mesylate | 108 | 36 |
| Megestrol Acetate | Megestrol Acetate | 107 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 30 |
| Irbesartan | Irbesartan | 105 | 35 |
| Meloxicam | Meloxicam | 105 | 61 |
| Fenofibrate | Fenofibrate | 100 | 27 |
| Eliquis | Apixaban | 99 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 94 | 37 |
| Ibuprofen | Ibuprofen | 93 | 44 |
| Tradjenta | Linagliptin | 91 | 25 |
| Ketoconazole | Ketoconazole | 86 | 31 |
| Finasteride | Finasteride | 85 | 27 |
| Dutasteride | Dutasteride | 82 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 28 |
| Trazodone Hcl | Trazodone Hcl | 78 | 28 |
| Lansoprazole | Lansoprazole | 76 | 30 |
| Lovastatin | Lovastatin | 74 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 26 |
| Nifedipine Er | Nifedipine | 73 | 20 |
| Glimepiride | Glimepiride | 72 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 26 |
| Benazepril Hcl | Benazepril Hcl | 71 | 22 |
| Furosemide | Furosemide | 69 | 30 |
| Baclofen | Baclofen | 68 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 66 | 17 |
| Loperamide | Loperamide Hcl | 66 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 45 |
| Amoxicillin | Amoxicillin | 64 | 47 |
| Fluocinonide | Fluocinonide | 61 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 27 |
| Mirtazapine | Mirtazapine | 60 | 29 |
| Lorazepam | Lorazepam | 57 | 16 |
| Xarelto | Rivaroxaban | 57 | 14 |
| Alprazolam | Alprazolam | 55 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 21 |
| Valsartan | Valsartan | 55 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 54 | 13 |
| Ozempic | Semaglutide | 48 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 46 | 46 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 18 |
| Procto-Med Hc | Hydrocortisone | 43 | 12 |
| Rybelsus | Semaglutide | 43 | 15 |
| Fosinopril Sodium | Fosinopril Sodium | 42 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 16 |
| Potassium Chloride | Potassium Chloride | 42 | 18 |
| Sertraline Hcl | Sertraline Hcl | 42 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | 12 |
| Terazosin Hcl | Terazosin Hcl | 40 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Ezetimibe | Ezetimibe | 39 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | 13 |
| Colchicine | Colchicine | 36 | 12 |
| Promethazine-Dm | Promethazine/Dextromethorphan | 36 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 34 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 33 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Restasis | Cyclosporine | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 30 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Cyclosporine | Cyclosporine | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | 15 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Prednisone | Prednisone | 27 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 15 |
| Temazepam | Temazepam | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Constulose | Lactulose | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Lactulose | Lactulose | 24 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | 16 |
| Estradiol | Estradiol | 21 | 11 |
| Mupirocin | Mupirocin | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 19 | suppressed |
| Benzonatate | Benzonatate | 18 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 17 | 17 |
| Azithromycin | Azithromycin | 16 | 16 |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 16 | suppressed |
| Sulindac | Sulindac | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Prozac | Fluoxetine Hcl | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Twinrix | Hepatitis A And B Vaccine/Pf | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Proctozone-Hc | Hydrocortisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,273.70 · 27 records | Amgen Inc. | AIRSUPRA, BRAFTOVI, BREZTRI, EVENITY, FARXIGA, JARDIANCE, Kerendia, LEQVIO, MEKTOVI, OTEZLA, Ozempic, PROLIA, REPATHA, Rybelsus, TUKYSA, Wegovy, ZENPEP | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error